Lv2
180 积分 2024-12-04 加入
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
18小时前
待确认
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
17天前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
17天前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
25天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
1个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Evolution of TROP2: Biological insights and clinical applications
3个月前
已完结
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
4个月前
已完结
皖公网安备34019202002308
